Welcome to the Medical Faculty of the University of Bonn

The human brain must be able to link memory content to the circumstances in which it occurs. Researchers in Bonn have now discovered how the human brain uses two different groups of neurons to store content and context separately. These nerve cell groups work together in a coordinated manner to form memories, rather than mixing signals in the activity of individual cells. The study results have now been published in the renowned journal Nature.

Two projects by researchers from the University of Bonn and University Hospital Bonn (UKB) have each been awarded up to €1 million in funding from the Federal Ministry of Research, Technology and Space’s “GO-Bio initial” program. The funds will be used to translate research findings from the life sciences into marketable products and services, e.g. through securing patent protection and spinning off start-ups.

MOG Antibody-associated Disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients contains antibodies against myelin oligodendrocyte glycoprotein (MOG), a protein in the myelin layer that surrounds the neurons in the brain. It is believed that these antibodies contribute to the destruction of this protective layer in the brain. Researchers at the University Hospital Bonn (UKB) and the Universities of Basel and Bonn, in collaboration with Yale School of Medicine and the German Center for Neurodegenerative Diseases (DZNE), have now deciphered the construction plan of the anti-MOG antibodies. The researchers see their findings on the misdirected immune response, which have now been published in the journal Neurology® Neuroimmunology & Neuroinflammation, as the basis for developing specific MOGAD therapies.

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to attack its own nervous system. This mechanism can accelerate the progression of multiple sclerosis, as researchers at the University of Basel, together with colleagues in Bonn, have shown in trials with mice. However, their results also open up opportunities for treatments that make use of the microbiome. The results have now been published in the journal Gut Microbes.